Delamanid and its Role in Drug-Resistant Tuberculosis
##plugins.themes.academic_pro.article.main##
Abstract
The World Health Organisation estimates that one-third of the world's population are currently infected with Tuberculosis bacillus, 10% of whom will develop the disease at some point in their lifetime. Poverty-Stricken countries of Africa and Asia bear the brunt of the disease partly due to an ominous synergy between mycobacterium bacteria and HIV. The recent recognition of MDR-TB and strains with more complex resistance patterns has stimulated the development of new TB medications including fluoroquinolones, oxazolidinones, diarylquinolines, nitroimidazopyrans. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR‑TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug‑drug interactions and better tolerability. The purpoe of this article is to bring forward, the various roles played by Delamanid in order to curb the problem of Multi-drug resistant Tuberculosis.
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Das, S., & Sehgal, V. K. (2017). Delamanid and its Role in Drug-Resistant Tuberculosis. International Journal of Medical and Dental Sciences, 1449–1453. https://doi.org/10.18311/ijmds/2017/18807
References
- Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology. 7th ed. Livingstone: Churchill Elsevier; 2012.p.634.
- Field SK. Safety and efficacy of Delamanid in the treatment of Multidrug resistant Tuberculosis. Clin Med Insights: Therapeutics 2013;5:137-49.
- Xavier AS, Lakshmanan M. Delamanid: A new armor in combating drug resistant tuberculosis. Journal of Pharmacology and Pharmacotherpeutics 2014;Jul-Sept;5(3): 222-4.
- Reid PT, Innes JA. Infection of the Respiratory system. Colledge NR, Walker BR, Ralston SH, editors. Davidson’s Principles and Practice of Medicine. 21st ed. Livingstone: Churchill Elsevier; 2010.p.688.
- Deck DH, Winston LG. Antimycobacterial Drugs. Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 12th ed. New Delhi: Mc Graw Hill Education; 2012.p.839.
- Sharma HL, Sharma KK. Principles of Pharmacology. 2nd ed. Hyderabad: Paras Medical Publisher; 2013.p.753.
- Rustomjee R, Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis. Dove Press journal: Infection and Drug Resistance 2015 Oct; 8:359-66.
- Lessem E. An Activist’s Guide to Delamanid (Deltyba). Treatment Action Group 2014 Sept:1-6.
- Sloan DJ, Lewis JM. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Trans R Soc Trop Med Hyg 2016;110:163–72.
- Gler MT, Skripconoka V, Garavito ES, Xiao H, Rivero JLC, Vasquez DEV, et al. Delamanid for Multidrug-Resistant Pulmonary Tuberculosis. N Engl J Med 2012 June;366(23):2151-60.
- Brigden G, Hewison C, Varaine F. New developments in the treatment of drugresistant tuberculosis: clinical utility of bedaquiline and delamanid. Dove Press journal: Infection and Drug Resistance 2015 Oct;8:367-78.
- Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, et al. In Vitro and In Vivo Activities of the Nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 2015 Jan;59(1):136-44.